StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
NGNENeurogene Inc.
stockpulse.co.kr
Nasdaq
$23.52▲ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $464.3MShares out 19.7M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 10.7Regular26.10.08 00:07
    SCHEDULE 13GOwnership#●●●#●●●

    Neurogene Inc.

    Prudential Financial Inc. has filed a Schedule 13G, reporting a beneficial ownership of more than 5% in Neurogene Inc. This filing officially discloses the institutional investor's stake in the company.…more

    $23.52+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.6Regular26.10.07 02:49
    SCHEDULE 13GOwnership

    Neurogene Inc.

    Jennison Associates LLC has filed a Schedule 13G statement regarding its beneficial ownership in Neurogene Inc. This filing serves as an official disclosure of the institutional investor's stake in the company.…more

    $23.52+0.13%vs prev close
    View filingShare
  • 10.2Regular26.10.03 03:49
    4Ownership

    Neurogene Inc.

    Executive Rachel McMinn of Neurogene Inc. filed a Form 4 report regarding changes in beneficial ownership of securities as of September 22, 2026. This filing serves as an official disclosure of the insider's updated equity holdings.…more

    $23.52+0.13%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 5d agoPre-market26.10.20 20:33
    #●●●#●●●

    Neurogene to Present Preclinical Data for NGN-401 Rett Syndrome Gene Therapy…more

    Neurogene will present preclinical data for its Rett syndrome gene therapy candidate, NGN-401, at the upcoming ESGCT Congress. This presentation will provide further insights into the program's progress ahead of potential clinical development.…more

    $23.52+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 10.6Regular26.10.07 02:59

    ●●●●●●●● ●●●●● ●●●●●●

    Jennison Associates reported an 11.1% stake in Neurogene as of September 30 in a recent 13G filing. This disclosure highlights significant institutional interest in the company's shares.…more

    $23.52+0.13%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →